Search

Displaying results 2541 - 2550 of 4646 in total
  1. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

  2. Drug

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

    go.drugbank.com/drugs/DB10991
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus that infects the mucosal la...

    Mixtures: PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, ADACEL 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADET
  3. Drug

    rPSGL-Ig

    go.drugbank.com/drugs/DB06256
    Investigational

    Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.

    Synonyms: rPSGL-Ig, rPSGL-1-Ig
  4. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

    Synonyms: 6-(4-((1S,3S)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one
  5. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  6. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired … [L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins.

  7. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].

    Synonyms: L-Asnase, L-asparaginase
  8. Target

    Aldo-keto reductase family 1 member C4

    go.drugbank.com/bio_entities/BE0000438
    TargetCarrierEnzymeHumans

    Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 3alpha/beta-, 17beta- and ...

    Synonyms: CHDR
  9. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous for the _F508del-CFTR_ gene - this represents approximately 70

  10. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814] Its distinguishing feature is its tetrameric structure carrying four chelated gadolinium ions with high relaxivity, which allows an adequately enhanced examination to be obtained while delivering … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity